Share Price and Basic Stock Data
Last Updated: January 2, 2026, 8:55 pm
| PEG Ratio | -3.93 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aarey Drugs & Pharmaceuticals Ltd operates within the pharmaceuticals sector, focusing on manufacturing and distributing a range of pharmaceutical products. As of the latest reporting, the company’s stock price stood at ₹66.3, with a market capitalization of ₹188 Cr. Revenue trends indicate volatility, with quarterly sales peaking at ₹210.35 Cr in March 2024, following a significant dip to ₹50.96 Cr in June 2023. The trailing twelve months (TTM) revenue is reported at ₹428 Cr, reflecting a decrease from ₹493 Cr in March 2022, signaling challenges in maintaining consistent sales growth. The company’s operational performance has fluctuated, evidenced by a decline in operating profit margin (OPM), which reported a low of 1.55% in March 2023, rebounding to 3.14% by September 2025. Such fluctuations highlight the need for strategic initiatives to stabilize revenue streams and enhance market position amidst competitive pressures in the pharmaceuticals industry.
Profitability and Efficiency Metrics
Profitability metrics for Aarey Drugs reveal a mixed performance. The net profit stood at ₹4 Cr, translating to a low return on equity (ROE) of 2.96% and return on capital employed (ROCE) of 6.38%. These figures are below industry averages, indicating potential inefficiencies in capital utilization. The company’s operating profit margin (OPM) averaged around 2.68% in the most recent fiscal year, which is relatively low compared to typical sector margins. The interest coverage ratio (ICR) stood at 2.73x, reflecting a moderate capacity to meet interest obligations but still suggests a vulnerability to rising interest rates. Furthermore, the cash conversion cycle (CCC) of 58 days indicates a relatively efficient inventory management process, although the debtor days have increased to 165, suggesting slow collections from customers. The combination of low profitability and mixed efficiency metrics necessitates a thorough review of operational strategies to enhance financial performance.
Balance Sheet Strength and Financial Ratios
Aarey Drugs’ balance sheet reflects a cautious financial position, with total borrowings reported at ₹51 Cr against reserves of ₹120 Cr. The debt-to-equity ratio stands at 0.25, indicating a conservative leverage approach, which is favorable in terms of financial stability. The company’s book value per share has shown a steady increase, reported at ₹48.67 as of March 2025, enhancing shareholder value. However, the price-to-book value (P/BV) ratio of 0.69x suggests that the stock is undervalued relative to its book value, potentially indicating market skepticism regarding future growth prospects. Additionally, the current ratio of 1.78 and quick ratio of 1.48 demonstrate solid liquidity, allowing the company to meet short-term obligations comfortably. Despite these strengths, the relatively low operating profit and net profit margins raise concerns about the sustainability of these financial ratios moving forward.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aarey Drugs indicates a diverse ownership structure, with promoters holding 44.80% as of March 2025, down from 50.04% in December 2022. This decline in promoter shareholding could reflect a shift in confidence among the company’s leadership. Foreign Institutional Investors (FIIs) have reduced their stake significantly to 1.13%, down from a peak of 3.92%, which can be interpreted as a lack of interest or confidence from external investors. Conversely, public shareholding has increased to 54.07%, suggesting growing retail investor interest, albeit in a context of declining institutional support. The number of shareholders has also decreased to 14,897, indicating potential consolidation among shareholders. This mixed sentiment among investors could impact the stock’s liquidity and overall market perception, necessitating efforts from management to restore confidence and attract institutional investment.
Outlook, Risks, and Final Insight
The outlook for Aarey Drugs remains cautiously optimistic, contingent upon its ability to stabilize revenue and improve profitability. Strengths include a solid balance sheet with manageable debt levels and a growing public shareholder base. However, significant risks persist, including declining profitability metrics and reduced institutional interest, which could pressure stock performance. The company must enhance operational efficiency and explore strategic partnerships to capitalize on market opportunities. Potential scenarios include a successful turnaround in sales, bolstered by innovative product launches or expansions into new markets, leading to improved investor sentiment. Conversely, failure to address profitability issues may result in further declines in investor confidence, impacting the company’s market position and growth trajectory. Management’s proactive engagement with shareholders and clear communication of growth strategies will be critical in navigating these challenges.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 216/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,742 Cr. | 435 | 479/192 | 98.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,248.81 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 76.26 | 62.47 | 162.88 | 50.96 | 57.83 | 76.48 | 210.35 | 126.91 | 105.14 | 133.79 | 108.10 | 102.21 | 84.16 |
| Expenses | 71.99 | 60.94 | 160.36 | 49.62 | 55.99 | 73.78 | 211.79 | 125.73 | 101.42 | 131.59 | 112.31 | 100.50 | 81.52 |
| Operating Profit | 4.27 | 1.53 | 2.52 | 1.34 | 1.84 | 2.70 | -1.44 | 1.18 | 3.72 | 2.20 | -4.21 | 1.71 | 2.64 |
| OPM % | 5.60% | 2.45% | 1.55% | 2.63% | 3.18% | 3.53% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.67% | 3.14% |
| Other Income | -0.94 | 0.48 | 0.84 | 0.70 | 0.84 | 0.29 | 5.14 | 1.58 | 0.02 | 0.68 | 7.54 | 1.55 | 0.79 |
| Interest | 0.59 | 0.71 | 0.20 | 0.42 | 0.41 | 0.47 | 0.40 | 0.96 | 0.49 | 0.58 | 1.30 | 1.04 | 1.26 |
| Depreciation | 0.42 | 0.55 | 1.02 | 0.89 | 1.27 | 1.06 | 1.15 | 0.47 | 1.51 | 0.90 | 0.41 | 0.49 | 0.69 |
| Profit before tax | 2.32 | 0.75 | 2.14 | 0.73 | 1.00 | 1.46 | 2.15 | 1.33 | 1.74 | 1.40 | 1.62 | 1.73 | 1.48 |
| Tax % | 9.05% | -33.33% | 83.18% | 0.00% | -22.00% | 30.14% | -0.47% | 6.77% | 8.62% | 48.57% | 71.60% | 20.81% | 31.08% |
| Net Profit | 2.12 | 1.00 | 0.36 | 0.72 | 1.23 | 1.02 | 2.15 | 1.24 | 1.60 | 0.72 | 0.47 | 1.37 | 1.02 |
| EPS in Rs | 0.84 | 0.39 | 0.14 | 0.28 | 0.48 | 0.40 | 0.77 | 0.44 | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 |
Last Updated: December 28, 2025, 11:04 am
Below is a detailed analysis of the quarterly data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 84.16 Cr.. The value appears to be declining and may need further review. It has decreased from 102.21 Cr. (Jun 2025) to 84.16 Cr., marking a decrease of 18.05 Cr..
- For Expenses, as of Sep 2025, the value is 81.52 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 100.50 Cr. (Jun 2025) to 81.52 Cr., marking a decrease of 18.98 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.64 Cr.. The value appears strong and on an upward trend. It has increased from 1.71 Cr. (Jun 2025) to 2.64 Cr., marking an increase of 0.93 Cr..
- For OPM %, as of Sep 2025, the value is 3.14%. The value appears strong and on an upward trend. It has increased from 1.67% (Jun 2025) to 3.14%, marking an increase of 1.47%.
- For Other Income, as of Sep 2025, the value is 0.79 Cr.. The value appears to be declining and may need further review. It has decreased from 1.55 Cr. (Jun 2025) to 0.79 Cr., marking a decrease of 0.76 Cr..
- For Interest, as of Sep 2025, the value is 1.26 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.04 Cr. (Jun 2025) to 1.26 Cr., marking an increase of 0.22 Cr..
- For Depreciation, as of Sep 2025, the value is 0.69 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.49 Cr. (Jun 2025) to 0.69 Cr., marking an increase of 0.20 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.48 Cr.. The value appears to be declining and may need further review. It has decreased from 1.73 Cr. (Jun 2025) to 1.48 Cr., marking a decrease of 0.25 Cr..
- For Tax %, as of Sep 2025, the value is 31.08%. The value appears to be increasing, which may not be favorable. It has increased from 20.81% (Jun 2025) to 31.08%, marking an increase of 10.27%.
- For Net Profit, as of Sep 2025, the value is 1.02 Cr.. The value appears to be declining and may need further review. It has decreased from 1.37 Cr. (Jun 2025) to 1.02 Cr., marking a decrease of 0.35 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.36. The value appears to be declining and may need further review. It has decreased from 0.48 (Jun 2025) to 0.36, marking a decrease of 0.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:21 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 200 | 213 | 246 | 396 | 349 | 354 | 298 | 348 | 493 | 419 | 396 | 474 | 428 |
| Expenses | 198 | 212 | 245 | 386 | 342 | 347 | 294 | 344 | 481 | 411 | 391 | 471 | 426 |
| Operating Profit | 1 | 1 | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 4 | 3 | 2 |
| OPM % | 1% | 1% | 0% | 2% | 2% | 2% | 1% | 1% | 2% | 2% | 1% | 1% | 1% |
| Other Income | 2 | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 7 | 10 | 11 |
| Interest | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 1 | 1 | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 6 | 6 |
| Tax % | 22% | 23% | 29% | 31% | 25% | 27% | 20% | 21% | 35% | 37% | 12% | 34% | |
| Net Profit | 1 | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 |
| EPS in Rs | 0.62 | 0.65 | 0.77 | 3.02 | 2.64 | 2.80 | 2.48 | 2.78 | 2.58 | 1.49 | 1.67 | 1.42 | 1.26 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 400.00% | 20.00% | 16.67% | -14.29% | 16.67% | 0.00% | -42.86% | 25.00% | -20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 400.00% | -380.00% | -3.33% | -30.95% | 30.95% | -16.67% | -42.86% | 67.86% | -45.00% |
Aarey Drugs & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 10% |
| 3 Years: | -1% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -7% |
| 3 Years: | -15% |
| TTM: | -26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 16% |
| 3 Years: | 20% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 4% |
| 3 Years: | 3% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:15 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 | 28 |
| Reserves | 18 | 19 | 20 | 31 | 57 | 63 | 69 | 75 | 88 | 92 | 105 | 110 | 120 |
| Borrowings | 6 | 11 | 15 | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 35 | 51 |
| Other Liabilities | 67 | 69 | 74 | 83 | 86 | 43 | 84 | 116 | 117 | 136 | 139 | 117 | 94 |
| Total Liabilities | 107 | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 294 |
| Fixed Assets | 4 | 6 | 8 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 16 | 25 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Other Assets | 102 | 109 | 117 | 130 | 157 | 133 | 181 | 218 | 230 | 277 | 289 | 272 | 267 |
| Total Assets | 107 | 115 | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 294 |
Below is a detailed analysis of the balance sheet data for Aarey Drugs & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 28.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 28.00 Cr..
- For Reserves, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2025) to 120.00 Cr., marking an increase of 10.00 Cr..
- For Borrowings, as of Sep 2025, the value is 51.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 35.00 Cr. (Mar 2025) to 51.00 Cr., marking an increase of 16.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 94.00 Cr.. The value appears to be improving (decreasing). It has decreased from 117.00 Cr. (Mar 2025) to 94.00 Cr., marking a decrease of 23.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 294.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 291.00 Cr. (Mar 2025) to 294.00 Cr., marking an increase of 3.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 25.00 Cr., marking an increase of 9.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 267.00 Cr.. The value appears to be declining and may need further review. It has decreased from 272.00 Cr. (Mar 2025) to 267.00 Cr., marking a decrease of 5.00 Cr..
- For Total Assets, as of Sep 2025, the value is 294.00 Cr.. The value appears strong and on an upward trend. It has increased from 291.00 Cr. (Mar 2025) to 294.00 Cr., marking an increase of 3.00 Cr..
Notably, the Reserves (120.00 Cr.) exceed the Borrowings (51.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -10.00 | -14.00 | 0.00 | 5.00 | -8.00 | -15.00 | -13.00 | -3.00 | -30.00 | -27.00 | -32.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 114 | 108 | 75 | 100 | 109 | 118 | 170 | 101 | 165 | 170 | 103 |
| Inventory Days | 10 | 7 | 3 | 5 | 16 | 23 | 21 | 20 | 11 | 26 | 33 | 36 |
| Days Payable | 119 | 117 | 108 | 71 | 84 | 40 | 98 | 120 | 86 | 115 | 123 | 81 |
| Cash Conversion Cycle | 9 | 5 | 3 | 9 | 32 | 92 | 42 | 69 | 26 | 76 | 80 | 58 |
| Working Capital Days | 52 | 49 | 40 | 34 | 69 | 77 | 99 | 91 | 68 | 89 | 106 | 89 |
| ROCE % | 6% | 7% | 7% | 22% | 14% | 12% | 8% | 9% | 10% | 6% | 6% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.42 | 1.67 | 1.49 | 2.72 | 2.79 |
| Diluted EPS (Rs.) | 1.42 | 1.67 | 1.49 | 2.72 | 2.79 |
| Cash EPS (Rs.) | 2.10 | 2.27 | 2.11 | 3.36 | 3.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 48.67 | 47.33 | 46.25 | 44.77 | 42.27 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 48.67 | 47.33 | 46.25 | 44.77 | 42.27 |
| Revenue From Operations / Share (Rs.) | 166.56 | 141.02 | 165.04 | 194.09 | 148.99 |
| PBDIT / Share (Rs.) | 4.47 | 4.07 | 4.12 | 5.52 | 4.98 |
| PBIT / Share (Rs.) | 3.78 | 3.46 | 3.50 | 4.74 | 4.59 |
| PBT / Share (Rs.) | 2.14 | 1.90 | 2.37 | 3.95 | 3.55 |
| Net Profit / Share (Rs.) | 1.41 | 1.67 | 1.49 | 2.58 | 2.79 |
| PBDIT Margin (%) | 2.68 | 2.88 | 2.49 | 2.84 | 3.34 |
| PBIT Margin (%) | 2.27 | 2.45 | 2.11 | 2.44 | 3.08 |
| PBT Margin (%) | 1.28 | 1.35 | 1.43 | 2.03 | 2.38 |
| Net Profit Margin (%) | 0.84 | 1.18 | 0.90 | 1.32 | 1.86 |
| Return on Networth / Equity (%) | 2.90 | 3.52 | 3.21 | 5.75 | 6.58 |
| Return on Capital Employeed (%) | 7.61 | 7.10 | 7.20 | 10.44 | 10.68 |
| Return On Assets (%) | 1.38 | 1.54 | 1.29 | 2.66 | 2.79 |
| Long Term Debt / Equity (X) | 0.01 | 0.02 | 0.03 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.25 | 0.23 | 0.32 | 0.12 | 0.18 |
| Asset Turnover Ratio (%) | 1.60 | 1.33 | 1.56 | 2.06 | 1.63 |
| Current Ratio (X) | 1.78 | 1.70 | 1.61 | 1.74 | 1.65 |
| Quick Ratio (X) | 1.48 | 1.49 | 1.44 | 1.63 | 1.51 |
| Inventory Turnover Ratio (X) | 11.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.73 | 2.61 | 3.65 | 7.01 | 4.79 |
| Interest Coverage Ratio (Post Tax) (X) | 1.86 | 2.07 | 2.32 | 4.27 | 3.68 |
| Enterprise Value (Cr.) | 129.30 | 155.10 | 97.10 | 119.06 | 71.62 |
| EV / Net Operating Revenue (X) | 0.27 | 0.39 | 0.23 | 0.24 | 0.20 |
| EV / EBITDA (X) | 10.17 | 13.59 | 9.29 | 8.50 | 6.15 |
| MarketCap / Net Operating Revenue (X) | 0.20 | 0.31 | 0.14 | 0.21 | 0.15 |
| Price / BV (X) | 0.69 | 0.94 | 0.51 | 0.92 | 0.54 |
| Price / Net Operating Revenue (X) | 0.20 | 0.31 | 0.14 | 0.21 | 0.15 |
| EarningsYield | 0.04 | 0.03 | 0.06 | 0.06 | 0.12 |
After reviewing the key financial ratios for Aarey Drugs & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.42. This value is below the healthy minimum of 5. It has decreased from 1.67 (Mar 24) to 1.42, marking a decrease of 0.25.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.42. This value is below the healthy minimum of 5. It has decreased from 1.67 (Mar 24) to 1.42, marking a decrease of 0.25.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 3. It has decreased from 2.27 (Mar 24) to 2.10, marking a decrease of 0.17.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.67. It has increased from 47.33 (Mar 24) to 48.67, marking an increase of 1.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 48.67. It has increased from 47.33 (Mar 24) to 48.67, marking an increase of 1.34.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 166.56. It has increased from 141.02 (Mar 24) to 166.56, marking an increase of 25.54.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 4.47. This value is within the healthy range. It has increased from 4.07 (Mar 24) to 4.47, marking an increase of 0.40.
- For PBIT / Share (Rs.), as of Mar 25, the value is 3.78. This value is within the healthy range. It has increased from 3.46 (Mar 24) to 3.78, marking an increase of 0.32.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.14. This value is within the healthy range. It has increased from 1.90 (Mar 24) to 2.14, marking an increase of 0.24.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 2. It has decreased from 1.67 (Mar 24) to 1.41, marking a decrease of 0.26.
- For PBDIT Margin (%), as of Mar 25, the value is 2.68. This value is below the healthy minimum of 10. It has decreased from 2.88 (Mar 24) to 2.68, marking a decrease of 0.20.
- For PBIT Margin (%), as of Mar 25, the value is 2.27. This value is below the healthy minimum of 10. It has decreased from 2.45 (Mar 24) to 2.27, marking a decrease of 0.18.
- For PBT Margin (%), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 10. It has decreased from 1.35 (Mar 24) to 1.28, marking a decrease of 0.07.
- For Net Profit Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 1.18 (Mar 24) to 0.84, marking a decrease of 0.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 2.90. This value is below the healthy minimum of 15. It has decreased from 3.52 (Mar 24) to 2.90, marking a decrease of 0.62.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.61. This value is below the healthy minimum of 10. It has increased from 7.10 (Mar 24) to 7.61, marking an increase of 0.51.
- For Return On Assets (%), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 5. It has decreased from 1.54 (Mar 24) to 1.38, marking a decrease of 0.16.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.25. This value is within the healthy range. It has increased from 0.23 (Mar 24) to 0.25, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.60. It has increased from 1.33 (Mar 24) to 1.60, marking an increase of 0.27.
- For Current Ratio (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 1.78, marking an increase of 0.08.
- For Quick Ratio (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.49 (Mar 24) to 1.48, marking a decrease of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 11.83. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 11.83, marking an increase of 11.83.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.73. This value is below the healthy minimum of 3. It has increased from 2.61 (Mar 24) to 2.73, marking an increase of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 3. It has decreased from 2.07 (Mar 24) to 1.86, marking a decrease of 0.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 129.30. It has decreased from 155.10 (Mar 24) to 129.30, marking a decrease of 25.80.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.27, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 10.17. This value is within the healthy range. It has decreased from 13.59 (Mar 24) to 10.17, marking a decrease of 3.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 1. It has decreased from 0.31 (Mar 24) to 0.20, marking a decrease of 0.11.
- For Price / BV (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.94 (Mar 24) to 0.69, marking a decrease of 0.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 1. It has decreased from 0.31 (Mar 24) to 0.20, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarey Drugs & Pharmaceuticals Ltd:
- Net Profit Margin: 0.84%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.61% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 2.9% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.48
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 52.5 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.25
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.84%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | E-34, M.I.D.C., Thane Maharashtra 401506 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mihir R Ghatalia | Chairman & Managing Director |
| Mr. Nimit Rajesh Ghatalia | Executive Director |
| Ms. Bina Rajesh Ghatalia | Woman Director |
| Mr. Chetan K Mehta | Independent Director |
| Mr. Anil Mandal | Independent Director |
| Mr. Lalit Radhakrishna Tulsiani | Independent Director |
FAQ
What is the intrinsic value of Aarey Drugs & Pharmaceuticals Ltd?
Aarey Drugs & Pharmaceuticals Ltd's intrinsic value (as of 05 January 2026) is ₹66.57 which is 0.41% higher the current market price of ₹66.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹188 Cr. market cap, FY2025-2026 high/low of ₹100/31.3, reserves of ₹120 Cr, and liabilities of ₹294 Cr.
What is the Market Cap of Aarey Drugs & Pharmaceuticals Ltd?
The Market Cap of Aarey Drugs & Pharmaceuticals Ltd is 188 Cr..
What is the current Stock Price of Aarey Drugs & Pharmaceuticals Ltd as on 05 January 2026?
The current stock price of Aarey Drugs & Pharmaceuticals Ltd as on 05 January 2026 is ₹66.3.
What is the High / Low of Aarey Drugs & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aarey Drugs & Pharmaceuticals Ltd stocks is ₹100/31.3.
What is the Stock P/E of Aarey Drugs & Pharmaceuticals Ltd?
The Stock P/E of Aarey Drugs & Pharmaceuticals Ltd is 52.5.
What is the Book Value of Aarey Drugs & Pharmaceuticals Ltd?
The Book Value of Aarey Drugs & Pharmaceuticals Ltd is 52.5.
What is the Dividend Yield of Aarey Drugs & Pharmaceuticals Ltd?
The Dividend Yield of Aarey Drugs & Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Aarey Drugs & Pharmaceuticals Ltd?
The ROCE of Aarey Drugs & Pharmaceuticals Ltd is 6.38 %.
What is the ROE of Aarey Drugs & Pharmaceuticals Ltd?
The ROE of Aarey Drugs & Pharmaceuticals Ltd is 2.96 %.
What is the Face Value of Aarey Drugs & Pharmaceuticals Ltd?
The Face Value of Aarey Drugs & Pharmaceuticals Ltd is 10.0.